NIAGEN BIOSCIENCE INC (NAGE) Stock Fundamental Analysis

NASDAQ:NAGE • US1710774076

5.18 USD
-0.15 (-2.81%)
At close: Feb 26, 2026
5.17 USD
-0.01 (-0.19%)
After Hours: 2/26/2026, 5:50:26 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

7

Overall NAGE gets a fundamental rating of 7 out of 10. We evaluated NAGE against 58 industry peers in the Life Sciences Tools & Services industry. NAGE has an excellent financial health rating, but there are some minor concerns on its profitability. NAGE is evaluated to be cheap and growing strongly. This does not happen too often! These ratings would make NAGE suitable for value and growth investing!


Dividend Valuation Growth Profitability Health

6

1. Profitability

1.1 Basic Checks

  • In the past year NAGE was profitable.
  • In the past year NAGE had a positive cash flow from operations.
  • In the past 5 years NAGE reported 4 times negative net income.
  • In multiple years NAGE reported negative operating cash flow during the last 5 years.
NAGE Yearly Net Income VS EBIT VS OCF VS FCFNAGE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M -20M -30M

1.2 Ratios

  • NAGE has a Return On Assets of 20.82%. This is amongst the best in the industry. NAGE outperforms 96.55% of its industry peers.
  • NAGE has a Return On Equity of 28.91%. This is amongst the best in the industry. NAGE outperforms 94.83% of its industry peers.
  • NAGE has a Return On Invested Capital of 20.22%. This is amongst the best in the industry. NAGE outperforms 94.83% of its industry peers.
Industry RankSector Rank
ROA 20.82%
ROE 28.91%
ROIC 20.22%
ROA(3y)-9.02%
ROA(5y)-25.18%
ROE(3y)-18.83%
ROE(5y)-52.67%
ROIC(3y)N/A
ROIC(5y)N/A
NAGE Yearly ROA, ROE, ROICNAGE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50 -100 -150

1.3 Margins

  • NAGE has a Profit Margin of 16.38%. This is amongst the best in the industry. NAGE outperforms 87.93% of its industry peers.
  • Looking at the Operating Margin, with a value of 15.48%, NAGE is in the better half of the industry, outperforming 79.31% of the companies in the same industry.
  • Looking at the Gross Margin, with a value of 63.89%, NAGE belongs to the top of the industry, outperforming 86.21% of the companies in the same industry.
  • In the last couple of years the Gross Margin of NAGE has grown nicely.
Industry RankSector Rank
OM 15.48%
PM (TTM) 16.38%
GM 63.89%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.17%
GM growth 5Y2.12%
NAGE Yearly Profit, Operating, Gross MarginsNAGE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. Health

2.1 Basic Checks

  • NAGE has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
  • The number of shares outstanding for NAGE has been increased compared to 1 year ago.
  • Compared to 5 years ago, NAGE has more shares outstanding
  • Compared to 1 year ago, NAGE has an improved debt to assets ratio.
NAGE Yearly Shares OutstandingNAGE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
NAGE Yearly Total Debt VS Total AssetsNAGE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

  • An Altman-Z score of 9.67 indicates that NAGE is not in any danger for bankruptcy at the moment.
  • NAGE's Altman-Z score of 9.67 is amongst the best of the industry. NAGE outperforms 93.10% of its industry peers.
  • NAGE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 9.67
ROIC/WACC1.87
WACC10.83%
NAGE Yearly LT Debt VS Equity VS FCFNAGE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M

2.3 Liquidity

  • NAGE has a Current Ratio of 4.12. This indicates that NAGE is financially healthy and has no problem in meeting its short term obligations.
  • NAGE has a better Current ratio (4.12) than 60.34% of its industry peers.
  • A Quick Ratio of 3.29 indicates that NAGE has no problem at all paying its short term obligations.
  • With a decent Quick ratio value of 3.29, NAGE is doing good in the industry, outperforming 62.07% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.12
Quick Ratio 3.29
NAGE Yearly Current Assets VS Current LiabilitesNAGE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

8

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 2300.00% over the past year.
  • The Revenue has grown by 36.04% in the past year. This is a very strong growth!
  • The Revenue has been growing by 16.56% on average over the past years. This is quite good.
EPS 1Y (TTM)2300%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%150%
Revenue 1Y (TTM)36.04%
Revenue growth 3Y13.87%
Revenue growth 5Y16.56%
Sales Q2Q%32.86%

3.2 Future

  • NAGE is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 59.22% yearly.
  • NAGE is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 22.85% yearly.
EPS Next Y85.64%
EPS Next 2Y73.46%
EPS Next 3Y64.95%
EPS Next 5Y59.22%
Revenue Next Year30.96%
Revenue Next 2Y25.55%
Revenue Next 3Y23.66%
Revenue Next 5Y22.85%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
NAGE Yearly Revenue VS EstimatesNAGE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 50M 100M 150M 200M
NAGE Yearly EPS VS EstimatesNAGE Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 0.2 -0.2 0.4 -0.4 0.6 -0.6

More info and screens

Find the best growth stocksShow best growing peers

7

4. Valuation

4.1 Price/Earnings Ratio

  • NAGE is valuated rather expensively with a Price/Earnings ratio of 21.58.
  • NAGE's Price/Earnings ratio is a bit cheaper when compared to the industry. NAGE is cheaper than 77.59% of the companies in the same industry.
  • Compared to an average S&P500 Price/Earnings ratio of 27.21, NAGE is valued a bit cheaper.
  • The Price/Forward Earnings ratio is 17.22, which indicates a rather expensive current valuation of NAGE.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of NAGE indicates a rather cheap valuation: NAGE is cheaper than 87.93% of the companies listed in the same industry.
  • NAGE is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 28.13, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 21.58
Fwd PE 17.22
NAGE Price Earnings VS Forward Price EarningsNAGE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, NAGE is valued a bit cheaper than 77.59% of the companies in the same industry.
  • 84.48% of the companies in the same industry are more expensive than NAGE, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 19.55
EV/EBITDA 17.99
NAGE Per share dataNAGE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0.5 1 1.5

4.3 Compensation for Growth

  • NAGE's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • NAGE has a very decent profitability rating, which may justify a higher PE ratio.
  • NAGE's earnings are expected to grow with 64.95% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.25
PEG (5Y)N/A
EPS Next 2Y73.46%
EPS Next 3Y64.95%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for NAGE!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

NIAGEN BIOSCIENCE INC

NASDAQ:NAGE (2/26/2026, 5:50:26 PM)

After market: 5.17 -0.01 (-0.19%)

5.18

-0.15 (-2.81%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)11-04
Earnings (Next)03-04
Inst Owners41.26%
Inst Owner ChangeN/A
Ins Owners0.01%
Ins Owner Change0.43%
Market Cap413.42M
Revenue(TTM)124.71M
Net Income(TTM)20.43M
Analysts85.45
Price Target16.12 (211.2%)
Short Float %11.27%
Short Ratio7.31
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)193.24%
Min EPS beat(2)180.11%
Max EPS beat(2)206.37%
EPS beat(4)4
Avg EPS beat(4)245.13%
Min EPS beat(4)180.11%
Max EPS beat(4)341.18%
EPS beat(8)8
Avg EPS beat(8)213.82%
EPS beat(12)12
Avg EPS beat(12)154.96%
EPS beat(16)14
Avg EPS beat(16)118.55%
Revenue beat(2)2
Avg Revenue beat(2)7.42%
Min Revenue beat(2)7.13%
Max Revenue beat(2)7.71%
Revenue beat(4)4
Avg Revenue beat(4)7.98%
Min Revenue beat(4)6.81%
Max Revenue beat(4)10.27%
Revenue beat(8)5
Avg Revenue beat(8)2.84%
Revenue beat(12)7
Avg Revenue beat(12)2.74%
Revenue beat(16)7
Avg Revenue beat(16)0.15%
PT rev (1m)0%
PT rev (3m)-1.5%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-8.33%
EPS NY rev (1m)0%
EPS NY rev (3m)26.39%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.66%
Valuation
Industry RankSector Rank
PE 21.58
Fwd PE 17.22
P/S 3.32
P/FCF 19.55
P/OCF 19.31
P/B 5.85
P/tB 5.87
EV/EBITDA 17.99
EPS(TTM)0.24
EY4.63%
EPS(NY)0.3
Fwd EY5.81%
FCF(TTM)0.26
FCFY5.12%
OCF(TTM)0.27
OCFY5.18%
SpS1.56
BVpS0.89
TBVpS0.88
PEG (NY)0.25
PEG (5Y)N/A
Graham Number2.19
Profitability
Industry RankSector Rank
ROA 20.82%
ROE 28.91%
ROCE 25.59%
ROIC 20.22%
ROICexc 135.09%
ROICexgc 138.1%
OM 15.48%
PM (TTM) 16.38%
GM 63.89%
FCFM 16.96%
ROA(3y)-9.02%
ROA(5y)-25.18%
ROE(3y)-18.83%
ROE(5y)-52.67%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.17%
GM growth 5Y2.12%
F-Score7
Asset Turnover1.27
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 33.55%
Cap/Sales 0.21%
Interest Coverage 250
Cash Conversion 106.62%
Profit Quality 103.52%
Current Ratio 4.12
Quick Ratio 3.29
Altman-Z 9.67
F-Score7
WACC10.83%
ROIC/WACC1.87
Cap/Depr(3y)21.85%
Cap/Depr(5y)22.95%
Cap/Sales(3y)0.27%
Cap/Sales(5y)0.33%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)2300%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%150%
EPS Next Y85.64%
EPS Next 2Y73.46%
EPS Next 3Y64.95%
EPS Next 5Y59.22%
Revenue 1Y (TTM)36.04%
Revenue growth 3Y13.87%
Revenue growth 5Y16.56%
Sales Q2Q%32.86%
Revenue Next Year30.96%
Revenue Next 2Y25.55%
Revenue Next 3Y23.66%
Revenue Next 5Y22.85%
EBIT growth 1Y4218.57%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year965.72%
EBIT Next 3Y173.71%
EBIT Next 5YN/A
FCF growth 1Y262.12%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y248.66%
OCF growth 3YN/A
OCF growth 5YN/A

NIAGEN BIOSCIENCE INC / NAGE FAQ

What is the fundamental rating for NAGE stock?

ChartMill assigns a fundamental rating of 7 / 10 to NAGE.


Can you provide the valuation status for NIAGEN BIOSCIENCE INC?

ChartMill assigns a valuation rating of 7 / 10 to NIAGEN BIOSCIENCE INC (NAGE). This can be considered as Undervalued.


Can you provide the profitability details for NIAGEN BIOSCIENCE INC?

NIAGEN BIOSCIENCE INC (NAGE) has a profitability rating of 6 / 10.


What are the PE and PB ratios of NIAGEN BIOSCIENCE INC (NAGE) stock?

The Price/Earnings (PE) ratio for NIAGEN BIOSCIENCE INC (NAGE) is 21.58 and the Price/Book (PB) ratio is 5.85.


What is the expected EPS growth for NIAGEN BIOSCIENCE INC (NAGE) stock?

The Earnings per Share (EPS) of NIAGEN BIOSCIENCE INC (NAGE) is expected to grow by 85.64% in the next year.